Table 2 Comparison of clinical characteristics between cases and controls in stage 1, stage 2 and joint analysis
Stage 1 | Stage 2 | Joint analysis | ||||
|---|---|---|---|---|---|---|
Characteristics | Cases (n = 503) | Controls (n = 490) | Cases (n = 814) | Controls (n = 779) | Cases (n = 1317) | Controls (n = 1269) |
Male (%) | 52.1 | 52.4 | 48.3 | 51.5 | 49.7 | 51.9 |
Age (years) | 53.6 ± 9.3 | 53.5 ± 9.2 | 54.5 ± 10.7 | 53.5 ± 9.7 | 54.2 ± 10.2 | 53.5 ± 9.5 |
SBP (mmHg) | 177.07 ± 28.05*⊿ | 117.47 ± 11.64⊿ | 148.98 ± 17.84* | 113.81 ± 9.86 | 159.70 ± 26.13* | 115.21 ± 10.72 |
DBP (mmHg) | 104.34 ± 12.28*⊿ | 75.05 ± 8.00⊿ | 90.62 ± 9.81* | 72.86 ± 7.57 | 95.85 ± 12.70* | 73.69 ± 7.81 |
BMI (kg/m2) | 26.32 ± 3.85* | 24.30 ± 3.56 | 25.79 ± 3.52* | 23.85 ± 3.37 | 26.00 ± 3.67* | 24.03 ± 3.43 |
TC (mg/dl) | 198.64 ± 37.50**** | 192.46 ± 40.06 | 197.34 ± 35.82* | 188.43 ± 38.15 | 197.84 ± 36.46* | 189.98 ± 38.93 |
HDL-C (mg/dl) | 48.80 ± 11.83*** | 51.31 ± 13.07 | 48.38 ± 11.14* | 49.39 ± 11.43 | 48.54 ± 11.41** | 50.13 ± 12.12 |
LDL-C (mg/dl) | 121.28 ± 32.64**** | 117.38 ± 32.98 | 122.08 ± 32.69* | 115.81 ± 34.36 | 121.78 ± 32.66* | 116.42 ± 33.83 |
TG (mg/dl) | 150.58 ± 94.21* | 126.62 ± 76.42 | 134.94 ± 65.09* | 116.67 ± 55.37 | 140.92 ± 77.85* | 120.51 ± 64.47 |
Glu (mg/dl) | 106.77 ± 32.40* | 99.09 ± 18.77 | 97.28 ± 10.90* | 94.80 ± 11.55 | 100.90 ± 22.25* | 96.46 ± 14.91 |
Cr (μmol/l) | 70.83 ± 15.21**** | 68.92 ± 12.12 | 70.92 ± 13.34 | 71.03 ± 12.93 | 70.89 ± 14.08 | 70.21 ± 12.66 |
Smokers (%) | 40.6 | 43.1 | 39.7 | 43.0 | 40.0 | 43.0 |
Drinkers (%) | 34.4 | 33.5 | 30.1 | 28.4 | 31.7 | 30.3 |
Anti-hypertensive medication (%) | 33.00 | 35.14 | 34.32 | |||